Prader-Willi Syndrome Investigational Therapy DCCR Enters Phase 3 Trial
A multicenter, Phase 3 clinical trial assessing diazoxide choline controlled-release (DCCR) for the treatment of Prader-Willi syndrome (PWS) recently was initiated, the trial’s sponsor, biopharmaceutical company Soleno Therapeutics, announced. Soleno is currently developing DCCR as a once-daily oral tablet for the treatment of PWS. The tablet is made of a…